Haemaccel (a registered trademark) is a type of intravenous colloid used in the prevention or treatment of shock associated with reduction in effective circulating blood volume due to hemorrhage, loss of plasma (burns, peritonitis, pancreatitis, crush injuries), or loss of water and electrolytes from persistent vomiting and diarrhea. Haemaccel contains degraded gelatin.
Haemaccel (also marketed as Emagel in Italy, "Polygeline" in China and Solucel in Venezuela) was originally brought to market by Hoechst AG and later acquired by Piramal Enterprises.
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|